{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:16:20Z","timestamp":1787678180329,"version":"build-2784847793"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LY20H310004"],"award-info":[{"award-number":["LY20H310004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.biopha.2024.116507","type":"journal-article","created":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T23:10:02Z","timestamp":1711926602000},"page":"116507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synergistic targeting of TrxR1 and ATM\/AKT pathway in human colon cancer cells"],"prefix":"10.1016","volume":"174","author":[{"given":"Xin","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116507_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.freeradbiomed.2013.07.036","article-title":"The thioredoxin antioxidant system","volume":"66","author":"Lu","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biopha.2024.116507_bib2","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.freeradbiomed.2022.07.020","article-title":"Thioredoxin reductase selenoproteins from different organisms as potential drug targets for treatment of human diseases","volume":"190","author":"Gencheva","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"3b","key":"10.1016\/j.biopha.2024.116507_bib3","first-page":"2425","article-title":"The thioredoxin-thioredoxin reductase system: over-expression in human cancer","volume":"23","author":"Lincoln","year":"2003","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2024.116507_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.redox.2015.12.004","article-title":"The thioredoxin system in breast cancer cell invasion and migration","volume":"8","author":"Bhatia","year":"2016","journal-title":"Redox Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116507_bib5","first-page":"324","article-title":"Expression of thioredoxin reductase 1 (TrxR1) in gastric cancer and its effect on the growth of gastric cancer cells","volume":"36","author":"Fan","year":"2020","journal-title":"Zhongguo Ying Yong Sheng Li Xue Za Zhi"},{"issue":"23","key":"10.1016\/j.biopha.2024.116507_bib6","doi-asserted-by":"crossref","first-page":"11408","DOI":"10.1073\/pnas.1903244116","article-title":"TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy","volume":"116","author":"McLoughlin","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.biopha.2024.116507_bib7","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1046\/j.1432-1327.2000.01703.x","article-title":"Thioredoxin reductase as a pathophysiological factor and drug target","volume":"267","author":"Becker","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.biopha.2024.116507_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1089\/ars.2009.2884","article-title":"Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer","volume":"12","author":"Selenius","year":"2010","journal-title":"Antioxid. Redox Signal"},{"issue":"5","key":"10.1016\/j.biopha.2024.116507_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s10637-021-01106-5","article-title":"Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer","volume":"39","author":"Abdullah","year":"2021","journal-title":"Invest N. Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2024.116507_bib10","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1021\/acs.jnatprod.1c00618","article-title":"A derivative of piperlongumine and ligustrazine as a potential thioredoxin reductase inhibitor in drug-resistant hepatocellular carcinoma","volume":"84","author":"Qian","year":"2021","journal-title":"J. Nat. Prod."},{"issue":"6","key":"10.1016\/j.biopha.2024.116507_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.tiv.2006.01.012","article-title":"Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1)","volume":"20","author":"Omata","year":"2006","journal-title":"Toxicol. Vitr."},{"issue":"5","key":"10.1016\/j.biopha.2024.116507_bib12","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.freeradbiomed.2011.11.034","article-title":"Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent","volume":"52","author":"Wang","year":"2012","journal-title":"Free Radic. Biol. Med"},{"issue":"Pt B","key":"10.1016\/j.biopha.2024.116507_bib13","article-title":"Auranofin: Past to Present, and repurposing","volume":"101","author":"Yamashita","year":"2021","journal-title":"Int Immunopharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2024.116507_bib14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1248\/cpb.c18-00767","article-title":"Potential anticancer activity of auranofin","volume":"67","author":"Onodera","year":"2019","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"8","key":"10.1016\/j.biopha.2024.116507_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/CAD.0b013e32834618bc","article-title":"Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy","volume":"22","author":"Wang","year":"2011","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13046-019-1215-y","article-title":"Curcuminoid WZ35 synergize with cisplatin by inducing ROS production and inhibiting TrxR1 activity in gastric cancer cells","volume":"38","author":"He","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.canlet.2016.02.058","article-title":"Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer","volume":"375","author":"Zou","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116507_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2024.116507_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2016.03.042","article-title":"Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals","volume":"387","author":"Prasad","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/jcrt.JCRT_862_16","article-title":"Oxidative stress and its role in cancer","volume":"17","author":"Jelic","year":"2021","journal-title":"J. Cancer Res. Ther."},{"issue":"34","key":"10.1016\/j.biopha.2024.116507_bib21","doi-asserted-by":"crossref","first-page":"36505","DOI":"10.18632\/oncotarget.5364","article-title":"Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer","volume":"6","author":"Zou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116507_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","article-title":"Akt in cancer: mediator and more","volume":"59","author":"Revathidevi","year":"2019","journal-title":"Semin Cancer Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116507_bib23","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1731","key":"10.1016\/j.biopha.2024.116507_bib24","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0283","article-title":"ATM-dependent pathways of chromatin remodelling and oxidative DNA damage responses","volume":"372","author":"Berger","year":"2017","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2024.116507_bib25","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.cellsig.2008.04.011","article-title":"ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells","volume":"20","author":"Halaby","year":"2008","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.biopha.2024.116507_bib26","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1074\/jbc.M410344200","article-title":"Full activation of PKB\/Akt in response to insulin or ionizing radiation is mediated through ATM","volume":"280","author":"Viniegra","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2024.116507_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-42667-5_1","article-title":"Targeting ROS-mediated crosstalk between autophagy and apoptosis in cancer","volume":"1260","author":"Gao","year":"2020","journal-title":"Adv. Exp. Med Biol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116507_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clinre.2018.01.005","article-title":"The role of ROS-induced autophagy in hepatocellular carcinoma","volume":"42","author":"Yuan","year":"2018","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"issue":"7","key":"10.1016\/j.biopha.2024.116507_bib29","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/auto.6.7.12113","article-title":"ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy","volume":"6","author":"Dewaele","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2024.116507_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fonc.2018.00160","article-title":"Phosphoinositide 3-kinase\/akt signaling and redox metabolism in cancer","volume":"8","author":"Koundouros","year":"2018","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2024.116507_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1083\/jcb.200512100","article-title":"Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism","volume":"175","author":"Pelicano","year":"2006","journal-title":"J. Cell Biol."},{"issue":"12","key":"10.1016\/j.biopha.2024.116507_bib32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.4161\/cbt.7.12.7067","article-title":"Cancer cell killing via ROS: to increase or decrease, that is the question","volume":"7","author":"Wang","year":"2008","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2024.116507_bib33","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41419-020-03136-y","article-title":"Photodynamic therapy induces autophagy-mediated cell death in human colorectal cancer cells via activation of the ROS\/JNK signaling pathway","volume":"11","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116507_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1040847","article-title":"MLN2238 exerts its anti-tumor effects via regulating ROS\/JNK\/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7150\/ijbs.33787","article-title":"Metformin induces cell cycle arrest, apoptosis and autophagy through ROS\/JNK signaling pathway in human osteosarcoma","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2024.116507_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-pathol-012513-104649","article-title":"The role of endoplasmic reticulum stress in human pathology","volume":"10","author":"Oakes","year":"2015","journal-title":"Annu Rev. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116507_bib37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41568-020-00312-2","article-title":"Endoplasmic reticulum stress signals in the tumour and its microenvironment","volume":"21","author":"Chen","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2697","article-title":"Autophagy: cellular and molecular mechanisms","volume":"221","author":"Glick","year":"2010","journal-title":"J. Pathol."},{"issue":"16","key":"10.1016\/j.biopha.2024.116507_bib39","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/cncr.31335","article-title":"Targeting autophagy in cancer","volume":"124","author":"Onorati","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2024.116507_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative stress and autophagy: the clash between damage and metabolic needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.biopha.2024.116507_bib41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/2159-8290.CD-19-0292","article-title":"Targeting autophagy in cancer: recent advances and future directions","volume":"9","author":"Amaravadi","year":"2019","journal-title":"Cancer Discov."},{"issue":"20","key":"10.1016\/j.biopha.2024.116507_bib42","doi-asserted-by":"crossref","first-page":"29359","DOI":"10.18632\/oncotarget.8833","article-title":"Wip1 suppresses ovarian cancer metastasis through the ATM\/AKT\/Snail mediated signaling","volume":"7","author":"Yin","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/1535-7163.MCT-08-1189","article-title":"The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt","volume":"9","author":"Li","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/10781552221112015","article-title":"Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021","volume":"29","author":"Kandemir","year":"2023","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12672-021-00439-0","article-title":"The gold complex auranofin: new perspectives for cancer therapy","volume":"12","author":"Abdalbari","year":"2021","journal-title":"Discov. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2024.116507_bib47","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"10.1016\/j.biopha.2024.116507_bib49","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/jcbfm.2008.80","article-title":"The role of Akt signaling in oxidative stress mediates NF-kappaB activation in mild transient focal cerebral ischemia","volume":"28","author":"Song","year":"2008","journal-title":"J. Cereb. Blood Flow. Metab."},{"issue":"33","key":"10.1016\/j.biopha.2024.116507_bib50","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1523\/JNEUROSCI.2111-04.2004","article-title":"Regulation of Cu\/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase\/Akt pathway and nuclear factor-kappaB","volume":"24","author":"Rojo","year":"2004","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.biopha.2024.116507_bib51","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2008.11.003","article-title":"Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis","volume":"14","author":"Nogueira","year":"2008","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2024.116507_bib52","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.18632\/oncotarget.6516","article-title":"Auranofin-mediated inhibition of PI3K\/AKT\/mTOR axis and anticancer activity in non-small cell lung cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib53","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1172\/JCI73941","article-title":"The role for autophagy in cancer","volume":"125","author":"White","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2024.116507_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2019.144323","article-title":"Interaction between DNA damage response and autophagy in colorectal cancer","volume":"730","author":"Roshani-Asl","year":"2020","journal-title":"Gene"},{"issue":"suppl 1","key":"10.1016\/j.biopha.2024.116507_bib55","article-title":"Autophagy and intermittent fasting: the connection for cancer therapy?","volume":"73","author":"Antunes","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.biopha.2024.116507_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-981-15-4272-5_25","article-title":"Autophagy and tumour radiotherapy","volume":"1207","author":"Gao","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"9","key":"10.1016\/j.biopha.2024.116507_bib57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2024.116507_bib58","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/cncr.31978","article-title":"Targeting autophagy using natural compounds for cancer prevention and therapy","volume":"125","author":"Deng","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-9966-33-8","article-title":"The activation of c-Jun NH\u2082-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells","volume":"33","author":"Jia","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2024.116507_bib60","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140141","article-title":"MAPK\/JNK signalling: a potential autophagy regulation pathway","volume":"35","author":"Zhou","year":"2015","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2024.116507_bib61","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","article-title":"Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation","volume":"21","author":"Xing","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116507_bib62","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ijc.32783","article-title":"Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer","volume":"147","author":"Myers","year":"2020","journal-title":"Int. J. Cancer"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224003913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T23:18:15Z","timestamp":1782343095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224003913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":62,"alternative-id":["S0753332224003913"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116507","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic targeting of TrxR1 and ATM\/AKT pathway in human colon cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116507"}}